Vitamin D3 Softgel OEM/ODM: Potency & Blend Uniformity Planning

Start with a defined ingredient and unit system

Specify cholecalciferol, the selected raw-material grade, and the declared amount per serving before choosing capsule dimensions. Vitamin D quantities may appear in micrograms or International Units. NIH states that one microgram equals 40 IU. Keep the formulation worksheet in one consistent unit system, with any conversion shown explicitly and independently checked.

A supplier may offer vitamin D3 as a concentrated preparation containing carrier ingredients rather than as undiluted cholecalciferol. Request the potency per gram, assay basis, complete composition, and relevant lot result. The weight of that preparation is not the same quantity as the weight of vitamin D3 it contributes to the formula.

Show the potency calculation before scaling

The starting calculation is target ingredient units divided by raw-material units per gram. As a hypothetical manufacturing example, supplying 100,000 IU to a defined development blend from a preparation specified at 1,000,000 IU per gram requires a nominal 0.1 gram of that preparation. These are blend arithmetic examples, not consumer intake recommendations.

Have qualified formulation staff account for the actual assay, measurement capability, and any justified processing or stability adjustments. Keep all assumptions visible; do not add an arbitrary overage simply because a vitamin is present at a small amount. A formula revision should record the reason for any adjustment and how the finished-product specification will be verified.

Choose sourcing and carrier together

NIH describes conventional vitamin D3 production from sheep-wool lanolin and the availability of an animal-free lichen source. If sourcing is part of the brand position, request documentation for the exact material. A lichen-derived vitamin does not establish a vegan softgel when the shell or another component has an animal origin.

The carrier selection should account for the raw-material preparation, shell compatibility, intended appearance, and proposed processing route. Ask whether D3 is expected to remain dissolved or dispersed in the final fill and how that state will be evaluated. Review the carrier ingredients on the supplier sheet before the brand agrees to an ingredient statement.

Define a meaningful uniformity plan

Because a concentrated ingredient may contribute a small proportion of the fill, ask how it will be measured, incorporated, and distributed through the blend. The process document should identify the preparation sequence, mixing approach, hold conditions, and sampling locations. A stable total fill weight alone cannot show that every capsule contains the intended vitamin contribution.

For a trial, consider samples that represent the beginning, middle, and end of filling, with the precise plan chosen by the qualified manufacturing and quality teams. Identify the analytical method and reporting basis before collecting samples. If results differ, review weighing records, material identity, blend handling, and sampling procedures rather than assuming additional mixing will solve the issue.

Reconcile test results with the final artwork

The product file should connect the formula calculation, capsule fill amount, intended serving, finished-product assay, and approved label declaration. FDA's supplement labeling guidance provides a framework for reviewing the Supplement Facts panel; use current applicable requirements when preparing artwork rather than copying an old label template without checking its units and format.

Agree on the stability program in the intended package and the evidence needed to support the declared amount over the chosen shelf life. For a sourcing or potency change, repeat the affected calculations and reviews. The release discussion should concern this formula revision and batch, not only whether a visually similar D3 capsule has previously been manufactured.

Common questions